Literature DB >> 28385325

iRECIST: A clarification of tumour response assessment in the immunotherapy era.

Charles Ferté1, Aurélien Marabelle2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28385325     DOI： 10.1016/j.ejca.2017.02.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  9 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

2.  Patterns of progression in patients treated for immuno-oncology antibodies combination.

Authors:  Alice Bernard-Tessier; Capucine Baldini; Eduardo Castanon; Patricia Martin; Stéphane Champiat; Antoine Hollebecque; Sophie Postel-Vinay; Andreea Varga; Rastilav Bahleda; Anas Gazzah; Jean-Marie Michot; Vincent Ribrag; Jean-Pierre Armand; Aurélien Marabelle; Jean-Charles Soria; Christophe Massard; Samy Ammari
Journal:  Cancer Immunol Immunother       Date:  2020-07-22       Impact factor: 6.968

Review 3.  [Radiological response assessment of modern immunotherapy using iRECIST].

Authors:  T Persigehl; T D Poeppel; O Sedlaczek
Journal:  Radiologe       Date:  2017-10       Impact factor: 0.635

4.  Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.

Authors:  Firas S Ahmed; Laurent Dercle; Gregory V Goldmacher; Hao Yang; Dana Connors; Ying Tang; Sanja Karovic; Binsheng Zhao; Richard D Carvajal; Caroline Robert; Michael L Maitland; Geoffrey R Oxnard; Lawrence H Schwartz
Journal:  Eur Radiol       Date:  2020-09-30       Impact factor: 7.034

Review 5.  The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.

Authors:  Alessandra Raimondi; Giovanni Randon; Pierangela Sepe; Melanie Claps; Elena Verzoni; Filippo de Braud; Giuseppe Procopio
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

6.  Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.

Authors:  Jiabu Ye; Xiang Ji; Phillip A Dennis; Hesham Abdullah; Pralay Mukhopadhyay
Journal:  Clin Pharmacol Ther       Date:  2020-07-18       Impact factor: 6.875

7.  Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.

Authors:  Qiao Yang; Mingjing Chen; Jiaoyang Gu; Kai Niu; Xianlan Zhao; Linpeng Zheng; Zihan Xu; Yongxin Yu; Feng Li; Lingxin Meng; Zhengtang Chen; Wenlei Zhuo; Luping Zhang; Jianguo Sun
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

8.  Elevated tumor markers for monitoring tumor response to immunotherapy.

Authors:  Yi Yang; Xiaolin Jiang; Yun Liu; Huan Huang; Yanli Xiong; He Xiao; Kan Gong; Xuemei Li; Xunjie Kuang; Xueqin Yang
Journal:  EClinicalMedicine       Date:  2022-04-08

Review 9.  Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction.

Authors:  Hong Wei; Hanyu Jiang; Bin Song
Journal:  Cancer Med       Date:  2019-08-05       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.